Working… Menu

Plantar Wart Treatment Using Adapalene Gel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04823845
Recruitment Status : Not yet recruiting
First Posted : April 1, 2021
Last Update Posted : July 9, 2021
Information provided by (Responsible Party):
Jonathan M Towarnicki, University of Louisville

Brief Summary:
This study seeks to research the efficacy of Adapalene 0.1% gel as a cost effective and low risk treatment option for plantar warts of the foot. Patients that present/diagnosed in designated clinics with plantar warts will be offered the option of being treated with regular superficial debridements of the epidermis and twice a day application of adapalene gel 0.1% under occlusion. Patients will be followed until resolution.

Condition or disease Intervention/treatment Phase
Plantar Wart Drug: Topical Adapalene Gel 0.1% Early Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: apply study treatment to single group of patients.
Masking: None (Open Label)
Masking Description: patient information will be kept secure and no individual identifiers will be used.
Primary Purpose: Treatment
Official Title: Plantar Wart Treatment Using Adapalene Gel
Estimated Study Start Date : August 20, 2021
Estimated Primary Completion Date : September 10, 2021
Estimated Study Completion Date : October 10, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Warts
Drug Information available for: Adapalene

Arm Intervention/treatment
Experimental: Plantar Wart Treatment Using Adapalene Gel 0.1%
patients treated for plantar warts with Adapalene 0.1% gel
Drug: Topical Adapalene Gel 0.1%
applying Adapalene Gel 0.1% to plantar warts topically

Primary Outcome Measures :
  1. Time Until Plantar Wart Resolution [ Time Frame: 30-60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • patients must be diagnosed with plantar warts

Exclusion Criteria:

  • pregnant women
  • previous wart treatment within the last 2 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04823845

Layout table for location contacts
Contact: Russell B Baker, DPM 8033512730
Contact: Jonathan Towarnicki, DPM

Sponsors and Collaborators
Jonathan M Towarnicki
Layout table for additonal information
Responsible Party: Jonathan M Towarnicki, Assistant Director Of Podiatric Medicine University of Louisville Hospital, University of Louisville Identifier: NCT04823845    
Other Study ID Numbers: 20.1175
First Posted: April 1, 2021    Key Record Dates
Last Update Posted: July 9, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will only be obtained/used by the researchers and no individual patient identifiers will be used.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Jonathan M Towarnicki, University of Louisville:
Additional relevant MeSH terms:
Layout table for MeSH terms
Foot Diseases
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Musculoskeletal Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents